Compass Therapeutics Inc. (CMPX) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Compass Therapeutics Inc. (NASDAQ: CMPX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.77 (-2.42% 1D, market cap $141.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CMPX ranks #631 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CMPX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -34.6%. By comparison, TARA (Protara Therapeutics Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -34.7%, cap $146.6M) and MOLN (Molecular Partners AG) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $134.3M). Among the 5-stock peer group, CMPX leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).
Per CMPX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001738021), Compass Therapeutics Inc. generated $203.9M in revenue (+28.6% YoY), -$66.5M in net income, and -$49.2M in free cash flow against $219.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While CMPX currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.43) and Max Pain ($0.81) forces dealer call-delta covering toward $7.22.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Compass Therapeutics Inc. (CMPX) dropped -2.42% to $0.77, trading at 2% of its 52-week range ($0.73 – $6.88). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
www.debelegger.nl report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
As published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary endpoint of PFS, with a 56% reduction in the risk of disease progression or de
Investing.com -- Emergent Biosolutions Inc (NYSE:EBS) shares dropped 1292% Friday after the company announced that Chief Financial Officer Richard Lindahl will retire at the end of 2026.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +28.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CMPX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CMPX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Compass Therapeutics Inc. (CMPX) ranks #631 by composite RQD confidence (34/100, grade E) and #611 by equity capitalization ($141.6M). Within this direct 5-issuer industry benchmark cohort, CMPX leads on earnings valuation at N/A trailing P/E, while CMPX leads on capital efficiency and profitability with -34.6% ROIC and — gross margin. MOLN currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with CMPX at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CMPX
ACTIVE
Compass Therapeutics Inc. | E | 34/100 | — | — | -34.6% | -2.42% | $141.6M | Benchmark Subject |
| TARA Protara Therapeutics Inc. | E | 32/100 | — | — | -34.7% | -2.82% | $146.6M | /tara-vs-cmpx → |
| MOLN Molecular Partners AG | D | 46/100 | — | — | — | -2.79% | $134.3M | /moln-vs-cmpx → |
| CRDL Cardiol Therapeutics Inc. (Class A) | D | 44/100 | — | — | — | -6.31% | $133.9M | /crdl-vs-cmpx → |
| STRO Sutro Biopharma Inc. | E | 32/100 | — | — | -35.0% | +0.11% | $150.9M | /stro-vs-cmpx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Compass Therapeutics Inc. (CMPX) reported GAAP revenue of $203.9M (+28.6% vs. FY2024 revenue of $158.6M , and +44.6% cumulative change since FY2023) , GAAP net income of -$66.5M, operating cash flow of -$49.1M, and free cash flow of -$49.2M (-9.5% YoY). On the balance sheet, CMPX closed FY2025 with $219.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $203.9M | -$66.5M | -$49.1M | -$49.2M | $219.6M | — |
| FY2024 (FY) | 2024-12-31 | $158.6M | -$49.4M | -$44.9M | -$44.9M | $140.4M | — |
| FY2023 (FY) | 2023-12-31 | $141.0M | -$42.5M | -$40.6M | -$40.6M | — | — |
As of 2026-11-03, Compass Therapeutics Inc. (NASDAQ: CMPX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.77 (-2.42% 1D, market cap $141.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CMPX ranks #631 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CMPX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -34.6%. By comparison, TARA (Protara Therapeutics Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -34.7%, cap $146.6M) and MOLN (Molecular Partners AG) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $134.3M). Among the 5-stock peer group, CMPX leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).
Per CMPX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001738021), Compass Therapeutics Inc. generated $203.9M in revenue (+28.6% YoY), -$66.5M in net income, and -$49.2M in free cash flow against $219.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
CMPX last traded at $0.77 (-2.42% on volume of 2,114,537 shares), positioning the stock -46.15% below its 50-day simple moving average ($1.43) and -75.71% below its 200-day simple moving average ($3.17). Across its 52-week range of $0.73 to $6.88, CMPX sits at the 0.7% percentile with a 14-day RSI of 27.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.87).
Compass Therapeutics Inc. (CMPX) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.77 (-2.42% 1D, market capitalization $141.6M).
Compass Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..1B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Compass Therapeutics Inc. (CMPX) reported $203.9M in annual revenue (up from $158.6M in FY2024, +28.6% YoY) and -$66.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($141.0M revenue, -$42.5M net income) through FY2025, CMPX scaled operating cash flow to -$49.1M and free cash flow to -$49.2M, backed by $219.6M in total assets against $0 in total debt.
Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), CMPX carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Compass Therapeutics Inc. (CMPX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
www.debelegger.nl report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
Here is why I am bullish on CMPX here at $0.79: Institutional accumulation and options positioning earn the strongest RQD pillar score (13/20) despite negative operating economics.. Compare CMPX's 0.0% operating margin and -34.6% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $0.75 are getting bought.
@BreakoutHunter Agree on the RQD 34/100 quality, though with 1.0 beta I'm scaling in with half-size at $0.79 and keeping dry powder in case we test $0.73.
Sitting on the sidelines or leaning short CMPX above $0.79. Operating losses widened from -$50.4M to -$72.8M over the reported periods while cash fell from $43.5M to $30.6M, with ROIC at -34.6%.. Until Fundamental Cash Engine (8/20) and FCF yield (0.0%) inflect higher, upside is capped near $6.88.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).